Dual-Acting Antibiotics Offer Hope Against Superbugs

Researchers from Wistar Institute have found a new category of compounds that merge the killing of bacterial pathogens that are drug resistant through the use of antibiotics, with a swift immune response used to fight antimicrobial resistance.

Last year, the WHO declared antimicrobial resistance (AMR) as a top public health threat. Estimates show that by the year 2050, infections that are antibiotic resistant could not only thrust upon the world economy a collective burden of $100 trillion but also claim the lives of nearly 10 million people every year. It does not help that the number of bacteria growing treatment resistant with the current antibiotics is increasing, with few new drugs in development. This has created a desperate need for better antibiotics to be developed in a bid to avert public health crisis.

The lead author of the study, who also happens to be an assistant professor in the Vaccine and Immunotherapy Center, Farokh Dotiwala explained that the researchers used a bilateral and creative approach to create novel molecules that may be used to eliminate infections that are challenging to treat while also boosting an individual’s immune response. The main objective of the study was to discover dual-acting immune antibiotics. The study’s findings were reported in the “Nature” journal.

The antibiotics being used at the moment typically target vital bacterial functions such as metabolic pathways, as well as protein and nucleic acid synthesis. However, through bacterial mutations that the antibiotics target, bacteria can gain a resistance to the drugs. This either pumps the drugs out or inactivates them.

Dotiwala stated that the scientists rationalized that using the immune system to target bacteria in different areas at the same time would make it difficult for the bacteria to develop resistance to the antibiotics.

Dotiwala and his colleagues centered their focus on a non-mevalonate pathway that is not present in humans but is vital for a majority of bacteria. This made it the best target for development of antibiotics. The pathway is in charge of the biogenesis of molecules needed in a majority of pathogenic bacteria for cell survival.

Dotiwala then partnered with the other senior author of the study and Wistar’s medicinal chemist Joseph Salvino to discover and synthesize novel molecules of IspH inhibitors that could penetrate the cell walls of the bacteria.

This approach helped the researchers show that the inhibitors triggered stronger bacterial elimination activity in the immune system. The first author of the study, Kumar Singh, explained that activation of the immune system made up another line of defense of the dual-acting immuno-antibiotics strategy.

It is also noteworthy to follow news about CNS Pharmaceuticals Inc. (NASDAQ: CNSP). This biotech company recently completed a phase 1 clinical trial of a drug candidate, and results show that at least 44% of the participants benefited from the potential treatment for malignant brain tumors.

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Archives

Select A Month

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050